Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Next Previous
X
Search
Trial Profile

Neoadjuvant Intralesional Injection of Talimogene Laherparepvec With Concurrent Preoperative Radiation in Patients With Locally Advanced Soft Tissue Sarcomas

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Jul 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Talimogene laherparepvec (Primary) ; Talimogene laherparepvec (Primary)
  • Indications Soft tissue sarcoma
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 19 Jun 2023 Planned End Date changed from 30 Jun 2024 to 1 Nov 2024.
    • 19 Jun 2023 Status changed from recruiting to active, no longer recruiting.
    • 04 Oct 2022 Status changed from suspended to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top